APOMORPHINE OLD DRUG ; NEW LIFE?
|
|
- Shanon Stone
- 5 years ago
- Views:
Transcription
1 APOMORPHINE OLD DRUG ; NEW LIFE? Dr Susan H Fox MRCP (UK), PhD Professor Neurology, University of Toronto Movement Disorders Clinic, Toronto Western Hospital CNSF, Halifax June 25 th 2018
2 DISCLOSURES Nature of relationship(s) Any direct financial payments including receipt of honoraria Membership on advisory boards or speakers bureaus Funded grants or clinical trials Name of for-profit or notfor-profit organization(s) WPC; CHDI; AAN; MDS Merz; Orion; Sunovion*; Palidan*; Teva; Seqirus; Zambon Michael J Fox Foundation for Parkinson Research; Edmund J Safra Foundation; Parkinson Canada; NIH; CIHR. Biotie; Cynapsus (Sunovion)* ; Eisai; Kyowa Description of relationship(s) Honoraria for participation on Committee/Conference Speaker/Chair. Advisory board and Speaker Funding for research Site PI for Clinical Trials * Companies developing Apomorphine products in Canada
3 Apomorphine Short-acting dopamine D2>D1 receptor agonist Derived from morphine; but no opioid properties
4 Clinical Uses Erectile dysfunction - first described by Ancient Egyptians (naturally occurring in blue lotus N. caerulea) Emetic Alcoholism; The Keeley Cure (1870s to 1900) contained apomorphine; animal medicine Parkinson's disease Weil, 1884 Schwab RS, Amador LV, Lettvin JY (1951). Apomorphine in Parkinson's disease. Transactions of the American Neurological Association. 56: 251 3
5 Use of Apomorphine in PD Subcutaneous administration due to low oral bioavailability (first pass metabolism) Intermittent injection Infusion Benefit in PD Effective anti-parkinsonian action Intermittent s.c. injection provides rapid onset More reliable that oral levodopa (no GI issues) Licensed for use in many countries (Available Europe since 1980s; US 2004 ) as adjunct in advanced PD for treating OFF periods
6 Efficacy of intermittent subcutaneous injections of apomorphine shown in many studies Rapid onset: mean onset in 6 to 14 minutes Short duration: mean duration of effect is 36 to 61.9 minutes Overall decrease in daily 'off' time is to - 4 hours of the waking day Average dose of each injection = 2 6 mg Up to 3x per day Review of 21 studies, including 8 DBRCT (n=126), 6 crossover; 13 open-label studies (n=202). Chen J J, Obering C. Clinical Therapeutics 2005; 27(11):
7 Dose dependent improvement in PD motor scores
8
9 Apomorphine : Side effects of drug Orthostatic hypotension = 10% Reason to discontinue 2% Dose-related Initial and long-term Rx
10 Apomorphine; available in Canada Intermittent subcutaneous injections Canada Jan 23 rd 2018: The CADTH Canadian Drug Expert Committee (CDEC) recommended apomorphine hydrochloride (apomorphine) be reimbursed for the acute, intermittent treatment of hypomobility off episodes ( end-of-dose wearing off and unpredictable on/off episodes) if the following criterion and conditions are met: Criterion: Apomorphine should only be used as adjunctive therapy in patients who are receiving optimized PD therapy (levodopa and derivatives and dopaminergic agonists) and still experiencing off episodes. Conditions: Patients treated with apomorphine should be under the care of a physician with experience in the diagnosis and management of PD. Reduction in price submitted unit price of $42.95 per 3 ml (30 mg) pen of apomorphine
11 Injectable Preloaded Pen 10mg/ml 3ml prefilled pen Pictorial representation only Inject s.c. into lower abdomen or outer thigh Store at room temp; lasts 48 hours after first opening. Do not use if solution has turned green.
12 Practicalities: Initial dose finding Pre-treat with anti-emetic Domperidone 10mg TID for 3 days (- > 50% discontinue after 6-8 weeks ) ECG (for QTc) (small dose related increased QTc if > 6mg used) In-clinic dose finding Suggested method Omit morning PD meds ie. OFF and 1h post 10mg domperidone Measure BP (lying and standing) Start with 1 mg or 2mg (- depending on BMI; risk of lowering BP) Assess benefit (ideally UPDRS part III) after 30 min and BP If no effect wait 1.5 hour post injections and repeat with 2 or 3mg If no effect bring back a second day or wait 1.5 hour post injection and repeat with 3 or 4 mg (total daily dose of apomorphine HCl should not exceed 100mg and individual bolus injections should not exceed 10 mg).
13 Practicalities: Long term use Requires patient (and physician education) Support for patient -? Telephone Ideal In clinic and home visit PD specialist Nurses?
14 Continuous subcutaneous apomorphine perfusion pump Licensed: 23 countries; UK>25 years.? Canada
15 Use of Apo Pump in PD Indication: Advanced PD with disabling motor fluctuations and dyskinesia Alternative to Levodopa-Carbidopa Gel Infusion (Duodopa) Alternative to Deep brain stimulation surgery Open-label/un-controlled studies/case series: Reduces OFF time Reduces dyskinesia, Reduces L-dopa dosing Phase III DBRCT (abstract only)
16 Apomorphine pumps reduce OFF time and Dyskinesia Garcia-Ruiz et al Mov Disord 2008
17 TOLEDO: randomized, double-blind, placebo-controlled Phase III study of subcutaneous apomorphine infusion in patients with Parkinson s disease and motor fluctuations not well controlled on optimized oral medical treatment Katzenschlager R, et al AAN Boston April patients in 23 centers, 7 countries 3 h OFF/day despite optimized treatment Slides courtesy of Dr Katzenschlager 52 week open-label phase COMT, catechol-o-methyl transferase inhibitor, DA, dopamine agonists; MAO-B, monoamine oxidase-b inhibitor.
18 Main results ON time without troublesome dyskinesia: treatment difference: 1 97 hours [95% CI: 0.69, 3.24; p=0.0008] Primary endpoint: absolute change in OFF time from baseline to Week 12 derived from patient diaries OFF time treatment difference hours (95% CI: -3.16, -0.62; p=0.0025) Safety and tolerability APO (n=54) Placebo (n=53) At least one treatment-emergent AE (TEAE) 50 (92.6%) 30 (56.6%) Most common TEAE ( 10% of patients) Skin nodules at infusion site Nausea Somnolence Skin erythema at infusion site Dyskinesia Headache Insomnia 24 (44.4%) 12 (22.2%) 12 (22.2%) 9 (16.7%) 8 (14.8%) 7 (13.0%) 6 (11.1%) 0 5 (9.4%) 2 (3.8%) 2 (3.8%) 0 2 (3.8%) 1 (1.9%) Serious AEs 5 (9.3%) 2 (3.8%) Patient Global Impression of Change: Favored apomorphine (p<0.0001) Level 1 evidence: Significant, clinically meaningful reduction in OFF time, Significant increase in ON time without troublesome dyskinesia
19 Additional Side effects of Apo Pump Subcutaneous nodules (50%) Ultrasound reduces induration Rotation of injection Rare: Coombs positive Haemolytic anemia (6%) ; check complete blood count and hemolytic parameters q6 monthly Symptoms = pallor, dyspnea, jaundice
20 Intervention ADD-ON THERAPY FOR MOTOR FLUCTUATIONS Efficacy conclusions Safety Implications for clinical practice Dopamine agonists Non-ergot Pramipexole Efficacious Acceptable risk Clinically useful Pramipexole ER Efficacious Clinically useful Ropinirole Efficacious Clinically useful Ropinirole PR Efficacious Clinically useful Rotigotine Efficacious Clinically useful Apomorphine Intermittent s.c Efficacious Clinically useful Apomorphine infusion Likely Efficacious Possibly Useful Piribedil Insufficient evidence Investigational Clinically useful Bromocriptine Likely Efficacious specialized monitoring Possibly useful Cabergoline Likely Efficacious Possibly useful Controlled release Insufficient evidence Investigational Extended IPX066 Efficacious Clinically useful Intestinal Infusion Efficacious Acceptable risk with specialized monitoring Clinically useful Ergot Pergolide Efficacious Acceptable risk with Levodopa/ peripheral decarboxylase inhibitor
21 Other delivery strategies for apomorphine? Prior failures with Intravenous Nasal rectal local skin reactions Acidic; ph 3.0 to 4.0 Intravenous - crystallizes causing thrombosis
22 Sublingual apomorphine? tried before.. Montastruc et al Sublingual apomorphine: a new pharmacological approach in Parkinson's disease? J Neural Transm Suppl 1995;45: Sublingual apomorphine was shown to reduce extrapyramidal symptoms. Sublingual apomorphine has the advantage of being easier to administer than subcutaneous injection. For the moment, the long-term use of sublingual apomorphine is limited by two major problems: 1. Time for dissolution and switch "on" (which is longer than after subcutaneous route) 2. Local side effects (stomatitis)... Further clinical studies using either more efficient (tablets with faster dissolution) and better tolerated sublingual formulations.should be carried on before recommending this approach in the treatment of Parkinson's disease.
23 Sublingual Apomorphine APL : soluble, sublingual, strip formulation. Thin bilayer apomorphine and optimising absorption ; second layer - buffer Drink water before using Place on bottom of tongue Don t swallow for 2 mins FDA granted APL fast track designation as a treatment for Parkinson s off episodes Aug New Drug Application for APL : filed with FDA March Health Canada: in submission
24 Open-label 20 PD subjects 78% subjects fully - ON at 30 mins 6/25/2018
25 Open-label dose-titration study of APL N = 76 PD with early AM OFF and total daily OFF time 2 hours/day Titration sequence for APL was 10mg, 15mg, 20mg, 25mg, 30mg. MDS-UPDRS Part III at 15, 30, 45, 60 and 90 minutes. Results» 83% of patients full ON with median dose 20mg. Mean Onset in 5-12 minutes. 15 Min ON in 22 % 30 Min ON in 59%» At 30 and 90 minutes there was a 22 and 16-point improvement in the MDS-UPDRS Part III, respectively. R. Hauser, S. Isaacson, A. Espay, R. Pahwa, D. Truong, E. Pappert, P. Gardzinski, B. Dzyngel, A. Agro, H. Fernandez. Efficacy of sublingual apomorphine film (APL ) for the treatment of OFF episodes in patients with Parkinson s disease: results from the Phase 3 study dose-titration phase [abstract]. Mov Disord. 2017; 32 (suppl 2).
26 Phase 3 APL for the Acute Treatment of OFF Episodes in Parkinson's Disease (CTH 300) 141 PD with motor fluctuations (total daily "OFF" time duration of 2 hours ) APL (10-35 mg) /placebo ; Two phases:- 1. In clinic open label dose titration: to determine dose at which patient achieved Full- ON: (22% discontinued; 8.5 % AE; 7% lack of benefit) week treatment phase: 109 subjects randomized to dose /placebo use of APL up to 5x /d (16% placebo v 37% APL discontinued) Primary endpoint: MDS UPDRS III at 30 min post dose after 12 weeks Multiple secondary endpoints % subjects with Full ON at 12 w; CGI;PGI; UPDRS II (ADL); home diary rate of Full ON after dose 1-2d prior to visit; PDQ36 (QAL); UPDRS III at 15 min Safety and tolerability Olanow CW et al Poster 2 nd Pan American Section of the International Parkinson and Movement Disorder Society meeting, Jun 23rd, 2018
27 Results Significantly improved MDS-UPDRS Part III score at 30 minutes (- 7.6 points v placebo) at Week 12 (P = ) 35% APL subjects full ON at 30 min v 16% placebo (P < 0.001) Median time to onset of effect = 22 min (22% ON at 11 min) Home diary 79% APL full ON at 30 min v 31% placebo Treatment-emergent adverse events in APL group (TEAEs led to withdrawals in 27% of APL v 9% in placebo) Nausea (27.0 %), Somnolence (14.9 %), Dizziness (14.2 %), (no significant OH) Oral mucosal erythema 7.4% = glossodynia, lip edema, lip swelling, oropharyngeal swelling, and throat irritation. CTH 301 NCT Long-term safety, efficacy (n = 226)
28 Comparison s.c. vs s.l apomorphine Subcutaneous Faster acting (onset 5-10 min) More reliable effect (93% on) Side effects Orthostatic hypotension can be significant; nodules Ease of use: assembling injections; Patient training/preference? Cost? Sublingual Onset in 20 min Variability in effect (31-78% full on at 30 min) Side effects less OH but oral mucosal reactions (idiosyncratic?) Ease of use: strip easier? Patient training/preference? Cost?
29 Open-Label, Randomized, Crossover Trial to evaluate sublingual administered APL (apomorphine) compared to subcutaneously administered apomorphine (NCT ) Open-label, crossover titration subjects will be randomly assigned to APL or APO s.c. and titrated to the dose that turns them from the practically defined "OFF" state to the full "ON" state. Then crossed over to the other drug and similarly titrated to the dose that provides a full "ON" state. PD with motor fluctuations (n = 85) End point Percentage of subjects preferring sublingual APL (apomorphine) compared to percentage of subjects preferring subcutaneous APO (apomorphine) at 3 months
30 Conclusions Apomorphine is a short acting dopamine D1,2 receptor agonist Effective anti parkinsonian action Uses: Advanced PD for disabling off periods especially sudden/unpredictable offs. Subcutaneous delivery (sublingual pending FDA/HC reviews) Side-effects : as per dopamine agonists plus subcutaneous effects local effects.
Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS INFUSION THERAPIES IN PARKINSON S DISEASE Apomorphine, T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR FLUCTUATIONS
More informationContinuous dopaminergic stimulation
Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (Final) APOMORPHINE HYDROCHLORIDE (MOVAPO PALADIN LABS INC.) Indication: Parkinson s disease RECOMMENDATION: The CADTH Canadian
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationUpdate in the Management of Parkinson s Disease
Update in the Management of Parkinson s Disease What s standard? What s new? What s coming? Bruno V. Gallo, M.D. Assistant Professor of Neurology, FIU Wertheim College of Medicine Director, Parkinson &
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Xadago GENERIC NAME Safinamide MANUFACTURER Newron Pharmaceuticals SpA holds license; granted approval. US WorldMeds, LLC exclusive licensee and distributor in the U.S. DATE OF APPROVAL March
More informationLiterature Scan: Anti-Parkinson s Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationScottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Drug, Treatment, Device name Co-careldopa 2000mg/500mg intestinal gel (Duodopa, Solvay Pharmaceuticals)
More informationPDL Class: Parkinson s Drugs
Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review: September 2013 Date of Last Review:
More informationApomorphine for the treatment of refractory motor fluctuations in late stage Parkinson's disease : an old drug revisited
Pérez Lloret, Santiago Apomorphine for the treatment of refractory motor fluctuations in late stage Parkinson's disease : an old drug revisited Preprint del documento publicado en European Journal of Neurology,
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationNovel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK
Novel approaches to the pharmacological treatment of Parkinson s disease Peter Jenner King s College UK Disclosures and Disclaimers Speakers fees and consultancy fees have been received from Britannia
More informationIndividual Study Table Referring to Part of Dossier: Volume: Page:
Synopsis Abbott Laboratories Name of Study Drug: DUODOPA Intestinal Gel Name of Active Ingredient: Levodopa-carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationNew Medicines Committee Briefing July 2011
New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationClinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: 05.16.17 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationShared Care Agreement Apomorphine For use in Parkinson s Disease
Shared Care Agreement Apomorphine For use in Parkinson s Disease This shared care agreement outlines suggested ways in which the prescribing responsibilities can be shared between the specialist and GP.
More informationEvidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson s Disease: 2001 to 2004
Movement Disorders Vol. 20, No. 5, 2005, pp. 523 539 2005 Movement Disorder Society Research Review Evidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson s Disease:
More informationFOR PARKINSON S DISEASE XADAGO NEXT?
FOR PARKINSON S DISEASE XADAGO can increase your daily on time without troublesome dyskinesia 1 Please see the complete Important Safety Information on pages 12-13 and the accompanying full Prescribing
More informationAPOMORPHINE (Adults) Shared Care Guidelines DRUG:
Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationREVIEW
REVIEW International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson s Disease Susan H. Fox, MRCP, PhD, 1,2 * Regina Katzenschlager,
More informationDeveloping a Sublingual Formulation of Apomorphine to Rapidly Convert Parkinson s Patients from OFF to ON State
Developing a Sublingual Formulation of Apomorphine to Rapidly Convert Parkinson s Patients from OFF to ON State Anthony Giovinazzo Noble Financial Investor Conference January 18, 2016 Forward Looking Statements
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationParkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust
n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels
More informationClinical Trial Results Posting
RD..3.2 V1. Page/Seite 1 of/von 5 CT Registry ID#: NCT2428 (ClinicalTrials.gov Identifier number) These results are supplied for informational purposes only. Prescribing decisions should be made based
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More informationSummary of Report Results
Summary of Report Results Abbott Laboratories Name of Study Drug: DUODOPA Intestinal Gel Name of Active Ingredient: Levodopa-Carbidopa Individual Study Table Referring to Part of Dossier: Volume: Page:
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationMedicines Management and the Unwell Parkinson s Patient
Medicines Management and the Unwell Parkinson s Patient Belinda Kessel Geriatrician and Movement Disorder Specialist Princess Royal University Hospital Orpington, Kent The Society for Acute Medicine, 7
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationAmantadine Extended-Release. Gocovri, Osmolex ER. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.21 Subject: Amantadine ER Page: 1 of 5 Last Review Date: June 22, 2018 Amantadine Extended-Release
More informationRotigotine provided sustained efficacy and tolerability in long term studies of early and late stage idiopathic Parkinson s disease
New data presented at the American Academy of Neurology meeting showed that Neupro (rotigotine transdermal system) improved both motor and non-motor symptoms of Parkinson s disease Analysis of RECOVER
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More informationWhat is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease
FPIN's Clinical Inquiries Treatment of Early Parkinson's Disease Clinical Question What is the best medical therapy for early Parkinson's disease? Evidence-Based Answer Treatment of early Parkinson's disease
More informationAnnouncing FDA Approval of GOCOVRI TM
Announcing FDA Approval of GOCOVRI TM August 24, 2017 2017 Adamas Pharmaceuticals, Inc. All Rights Reserved. 1 Forward-looking Statements Statements contained in this presentation regarding expected future
More informationAPOKYN (apomorphine hydrochloride)
APOKYN (apomorphine hydrochloride) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationEuropean Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations
July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex
More informationSurgical Management of Parkinson s Disease
Surgical Management of Parkinson s Disease Shyamal H. Mehta MD, PhD Assistant Professor of Neurology, Movement Disorders Division Mayo Clinic College of Medicine Mayo Clinic, Arizona 2016 MFMER slide-1
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationAbbreviated Class Update: Parkinson s Drugs. Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. MAO- B** Inhibitors
Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Abbreviated Class Update: Parkinson s Drugs Month/Year of Review: November 2013 End of literature
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationOverview of Parkinson s disease Research at University of Colorado
Overview of Parkinson s disease Research at University of Colorado Brian D. Berman, MD, MS May 12, 2018 University of Colorado Movement Disorders Center Terminology Basic science pure/fundamental scientific
More informationRasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature
Neurol Ther (2014) 3:41 66 DOI 10.1007/s40120-013-0014-1 REVIEW Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature Michele Pistacchi Francesco Martinello Manuela
More informationLet s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016
Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016 What is Parkinson s? Parkinson's is a progressive neurological condition. People
More informationFinal Appraisal Report. ) for the treatment of idiopathic Parkinson s disease. Ropinirole prolonged-release (Requip XL. GlaxoSmithKline UK
Final Appraisal Report Ropinirole prolonged-release (Requip XL ) for the treatment of idiopathic Parkinson s disease GlaxoSmithKline UK Advice No: 1409 August 2009 Recommendation of AWMSG Ropinirole prolonged-release
More informationIs Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Safinamide Effective as an Add-on
More informationParkinson s Disease medications
Parkinson s Disease medications In correlation to the Unified Parkinson s disease rating scale Ayaan Mohamed Degree Thesis in Pharmacy 15 ECTS Bachelor s Level Report passed: Spring 2017 Supervisor: Miles
More informationNeupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease
For the attention of accredited medical writers only Neupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease Detailed
More informationACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
More informationNew data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome
New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome Latest safety and efficacy results for rotigotine in the treatment of moderate to
More informationSwitching from pergolide to pramipexole in patients with Parkinson s disease
J Neural Transm (2001) Switching 108: 63 70 from pergolide to pramipexole in PD 63 Switching from pergolide to pramipexole in patients with Parkinson s disease P. A. Hanna 1,2, L. Ratkos 2, W. G. Ondo
More informationUpdate on Parkinson s disease and other Movement Disorders October 2018
Update on Parkinson s disease and other Movement Disorders October 2018 DR. JONATHAN EVANS CONSULTANT IN NEUROLOGY QUEEN S MEDICAL CENTRE NOTTINGHAM Disclosures: Honoraria UCB, Britannia, Allergan, AbbVie
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More informationNon-Oral Drug Delivery Strategies: From Early Diagnosis to Advanced Treatments
Florida International University FIU Digital Commons HWCOM Faculty Publications Herbert Wertheim College of Medicine 8-2015 Non-Oral Drug Delivery Strategies: From Early Diagnosis to Advanced Treatments
More informationTitan Pharmaceuticals Overview
Corporate Presentation July 2014 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
More informationBORDEAUX MDS WINTER SCHOOL FOR YOUNG
BORDEAUX MDS WINTER SCHOOL FOR YOUNG NEUROLOGISTS HOW TO EVALUATE MOTOR COMPLICATIONS IN PARKINSON'S DISEASE T. Henriksen Tove Henriksen, MD MDS Clinic University Hospital of Bispebjerg, Copenhagen MOTOR
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationRECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease
For the attention of Accredited Medical Writers Only RECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease Post hoc analyses of RECOVER study suggested
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationRotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research
Rotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research Synthetic DRUG PROFILE Introduction Parkinson s disease (PD) is a neurodegenerative disorder
More informationCONTINUOUS THERAPY BECAUSE LIFE GOESON
CONTINUOUS THERAPY BECAUSE LIFE GOESON Investigating the effectiveness and safety of ND0612, an investigational medicine for patients with advanced Parkinson s Disease New medication limited by Federal
More informationParkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care
Parkinson's Disease Prescribing Guidelines for use in Primary and Secondary Care 2017 Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care Document Description Document Type
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationS H A R E D C A R E G U I D E L I N E Drug: Apomorphine Indication Parkinson s Disease
S H A R E D C A R E G U I D E L I N E Drug: Apomorphine Indication Parkinson s Disease Introduction Indication: Treatment of Parkinson s Disease with Apomorphine Background: Patients with Parkinson s disease
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationXADAGO (safinamide) oral tablet
XADAGO (safinamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationAnand R, 1 Borgohain R, 2 Stocchi F, 3 Giuliani R, 4 Rice P, 5 Forrest E, 4 Lucini V, 4 for the Study 016/018 Investigators IL, USA
First 2-year, placebo-controlled study in Parkinson s disease patients with motor fluctuations indicates safinamide may benefit patients with more severe dyskinesia Anand R, 1 Borgohain R, 2 Stocchi F,
More informationDrug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)
Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl
More informationCAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections
CAM2038 A new liquid-lipid crystal depot buprenorphine: A dose-ranging suite of weekly and monthly subcutaneous depot injections Dr. Fredrik Tiberg Assoc. Prof. President & CEO, Head R&D, Camurus Lund,
More informationPatients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment
For the attention of accredited medical writers only Patients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment Data presented at the 7
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationSmall-Cap Research. Cynapsus Therapeutics Inc. (V.CTH-TSX)
Small-Cap Research August 23, 2013 Jason Napodano, CFA John Tucker, PhD 312-265-9421 / jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Cynapsus Therapeutics Inc. CYNAF Second
More informationDr Barry Snow. Neurologist Auckland District Health Board
Dr Barry Snow Neurologist Auckland District Health Board Dystonia and Parkinson s disease Barry Snow Gowers 1888: Tetanoid chorea Dystonia a movement disorder characterized by sustained or intermittent
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationOptimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
EXPERT OPINION Optimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective David J Brooks Division of Neuroscience, Faculty
More information